Breast Cancer Breakthrough Award Levels 3 and 4
The summary for the Breast Cancer Breakthrough Award Levels 3 and 4 grant is detailed below.
This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants.
Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact.
If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.
Breast Cancer Breakthrough Award Levels 3 and 4: The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:
Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome.
Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement. Two additional funding levels, Funding Levels 1 and 2, are available under a different Program Announcement/Funding Opportunity (W81XWH-16-BCRP-BREAKTHROUGH_FL12). It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:
• Funding Level 3: Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply.
• Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. PIs are expected to have experience in successfully leading large-scale projects.
Note: An invited oral presentation is a requirement for application review of Funding Level 4 projects, as described in Section II.C., Full Application Submission Content and Forms.
Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive collaborations between investigators. The Partnering PI Option is structured to accommodate two PIs, referred to as the Initiating PI and the Partnering PI, each of whom will each receive a separate award. The Initiating and Partnering PIs have different submission requirements; however, both PIs should contribute significantly to the development of the proposed research project including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. New collaborations are encouraged, but not required. It is the responsibility of the PIs to describe how their combined expertise will better address the research question and explain why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly addressing distinct research questions. Applications submitted by a mentor and his/her current postdoctoral fellow or junior investigator as Initiating and Partnering PIs do not meet the intent of the Partnering PI Option.
Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term, but must be significant and move beyond an incremental advancement. Applications must articulate the pathway to making a clinical impact for individuals with, or at risk for, breast cancer, even if clinical impact is not an immediate outcome.
Research Scope: Research proposed under this award mechanism may be small- to large-scale projects, at different stages of idea and research development. Two different funding levels, based on the scope of the research, are available under this Program Announcement. Two additional funding levels, Funding Levels 1 and 2, are available under a different Program Announcement/Funding Opportunity (W81XWH-16-BCRP-BREAKTHROUGH_FL12). It is the responsibility of the Principal Investigator (PI) to select the funding level that is most appropriate for the research proposed. The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:
• Funding Level 3: Advanced translational studies that have potential for near-term clinical investigation. Small-scale clinical trials may apply.
• Funding Level 4: Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Near-term clinical impact is expected. PIs are expected to have experience in successfully leading large-scale projects.
Note: An invited oral presentation is a requirement for application review of Funding Level 4 projects, as described in Section II.C., Full Application Submission Content and Forms.
Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive collaborations between investigators. The Partnering PI Option is structured to accommodate two PIs, referred to as the Initiating PI and the Partnering PI, each of whom will each receive a separate award. The Initiating and Partnering PIs have different submission requirements; however, both PIs should contribute significantly to the development of the proposed research project including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. New collaborations are encouraged, but not required. It is the responsibility of the PIs to describe how their combined expertise will better address the research question and explain why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from submitting as a Partnering PI on multiple applications unless they are clearly addressing distinct research questions. Applications submitted by a mentor and his/her current postdoctoral fellow or junior investigator as Initiating and Partnering PIs do not meet the intent of the Partnering PI Option.
| Federal Grant Title: | Breast Cancer Breakthrough Award Levels 3 and 4 |
| Federal Agency Name: | Dept of the Army USAMRAA |
| Grant Categories: | Science and Technology |
| Type of Opportunity: | Discretionary |
| Funding Opportunity Number: | W81XWH-16-BCRP-BREAKTHROUGHFL34 |
| Type of Funding: | Cooperative Agreement, Grant |
| CFDA Numbers: | 319331 |
| CFDA Descriptions: | Military Medical Research and Development |
| Current Application Deadline: | Aug 11, 2016 |
| Original Application Deadline: | Aug 11, 2016 |
| Posted Date: | Mar 1, 2016 |
| Creation Date: | Mar 1, 2016 |
| Archive Date: | Sep 10, 2016 |
| Total Program Funding: | $43,500,000 |
| Maximum Federal Grant Award: | none |
| Minimum Federal Grant Award: | none |
| Expected Number of Awards: | 5 |
| Cost Sharing or Matching: | No |
- Applicants Eligible for this Grant
- Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"
- Grant Announcement Contact
- Phone: 301-682-5507
Email: [email protected]
CDMRP Help Desk
Dept. of the Army -- USAMRAA 301-619-7144